StrokeNCT06253000
Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium
A study testing Cryoablation and Radiofrequency ablation in people with Stroke and Acute Cerebrovascular Accident, run by Bakulev Scientific Center of Cardiovascular Surgery at 1 site in Russia.
Trial summary
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Read more about this study
- Who is it for?
- Ages 18 to 80 years
- Conditions the study is for
- Stroke, Acute Cerebrovascular Accident, Transient Ischemic Attack
- What is being tested?
- Cryoablation and Radiofrequency ablation
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 158 participants
- Where
- 1 siteRussia
- Study dates
- 10 Jun 2023to 30 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 80 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age over 18 years old;
- Atrial fibrillation resistant to antiarrhythmic therapy;
- Persistent and long-persisting form of atrial fibrillation;
- The patient's consent to participate in the study.
Who cannot join
- Age under 18 and over 80 years old;
- The presence of another cardiac pathology requiring surgical treatment;
- Congenital heart defects;
- Previous "open" cardiac surgery;
- Bone marrow diseases;
- Pathology of the blood coagulation system;
Show all 12Show fewer
- The left ventricular ejection fraction is less than 40%;
- Moderate to severe renal insufficiency (creatinine clearance <50 ml/min);
- Drug-resistant hypertension (despite hypotensive therapy);
- Organically altered mitral valve;
- There are reasons to assume that the patient will not show up for subsequent visits (control points of the study) for various reasons;
- The patient's participation in another clinical trial.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Russia1 site, 1 recruiting
- Recruiting
Bakulev National Medical Research Center for Cardiovascular Surgery
Moscow, 121552
Grayr Avanesyan, +7(987)-333-18-88, gaavanesyan@bakulev.ru
About this study
Official title: Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.
The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA).
The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.
- Conditions
- Stroke, Acute Cerebrovascular Accident, Transient Ischemic Attack, Death, Atrial Fibrillation Recurrent
- Being tested
- Cryoablation, Radiofrequency ablation
- Keywords
- atrial fibrillation, radiofrequency ablation, cryoablation, left atrium, the posterior wall of the left atrium, atrial remodeling
- Medical subject headings
- Stroke, Ischemic Attack, Transient, Death, Atrial Fibrillation, Atrial Remodeling
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
CryoablationProcedure or surgery
Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium.
Radiofrequency ablationProcedure or surgery
Radiofrequency ablation of pulmonary veins according to the "box isolation" type using a non-fluoroscopic navigation system.
| Study group | Role | What they receive |
|---|---|---|
| Cryoablation | Active comparator | Cryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium. Receives: Procedure: Cryoablation |
| Radiofrequency ablation | Active comparator | Radiofrequency ablation of pulmonary veins according to the "box isolation" type using a non-fluoroscopic navigation system. Receives: Procedure: Radiofrequency ablation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Cerebral events
The number of patients who had a stroke or acute cerebrovascular accident or a transient ischemic attack within 24 months after ablation.
Measured: From the date of ablation until the date of the event, assessed up to 24 months.
Secondary outcomes (4)
Hospital mortality
The number of patients who died in the hospital.
Measured: From the date of ablation until the date of death, assessed up to 5 days.
Non-lethal events
Number of participants with non-lethal events. The main hospital non-lethal events (bleeding, tamponade, perforation of the walls of the heart, damage to the esophagus).
Measured: From the date of ablation to the date of any of the listed events, assessed up to 5 days.
Recurrence of AF
The number of patients with recurrent atrial fibrillation after surgery.
Measured: From the date of ablation until the date of recurrent atrial fibrillation, assessed up to 24 months.
Long-term mortality
The number of patients who died during the follow-up period.
Measured: From the date of ablation until the date of death, assessed up to 24 months.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Feb 2024
- Study start10 Jun 2023
- Primary completion30 Dec 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for StrokeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- A randomized double-blind controlled trial in two groups
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 158 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Bakulev Scientific Center of Cardiovascular Surgery
- Sponsor type
- Other government
- Responsible party
- Sponsor
- Investigators
- Andrey Filatov, Principal investigator, Bakulev Scientific Center for Cardiovascular Surgery
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06253000
- Sponsor's protocol ID
- #4.10.11.2022
- Status last verified
- Jul 2025
- First submitted
- 2 Feb 2024
- Last updated
- 20 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparative Analysis of Radiofrequency and Cryoablation of the Posterior Wall of the Left Atrium in Patients With Persistent Atrial Fibrillation
- ClinicalTrials.gov ID
- NCT06253000
- Acronym / sponsor ID
- #4.10.11.2022
- Conditions
- Stroke, Acute Cerebrovascular Accident, Transient Ischemic Attack, Death, Atrial Fibrillation Recurrent
- Keywords
- atrial fibrillation, radiofrequency ablation, cryoablation, left atrium, the posterior wall of the left atrium, atrial remodeling
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 158 participants (estimated)
- Lead sponsor
- Bakulev Scientific Center of Cardiovascular SurgeryOther government
- Study start
- 10 Jun 2023 (actual)
- Primary completion
- 30 Dec 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 12 Feb 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Atrial fibrillation (AF) is the cause of 20% of strokes, and the risk of stroke in a person suffering from this arrhythmia increases by 5 times. Ischemic stroke in patients with AF is often fatal and, compared with stroke of other etiology, leads to the most pronounced disability and more often recurs. Accordingly, the risk of death in patients with AF-related stroke is 2 times higher, and treatment costs increase 1.5 times.
The main interventional method of treating AF, available in most medical institutions, is the use of radio frequency and/or cryoenergy to eliminate destructive damage to the left atrium (LA).
The aim of this study is to compare two different interventional methods and identify predictors of recurrence in patients with persistent and long-term AF.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (participant)
- Number of arms
- 2
- Model description
- A randomized double-blind controlled trial in two groups
| Arm | Type | Receives |
|---|---|---|
| Cryoablation | Active comparator | Procedure: CryoablationCryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium. |
| Radiofrequency ablation | Active comparator | Procedure: Radiofrequency ablationRadiofrequency ablation of pulmonary veins according to the "box isolation" type using a non-fluoroscopic navigation system. |
Who may qualify
- Ages
- 18 to 80 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age over 18 years old;
- Atrial fibrillation resistant to antiarrhythmic therapy;
- Persistent and long-persisting form of atrial fibrillation;
- The patient's consent to participate in the study.
Key exclusion criteria (12 listed)
- Age under 18 and over 80 years old;
- The presence of another cardiac pathology requiring surgical treatment;
- Congenital heart defects;
- Previous "open" cardiac surgery;
- Bone marrow diseases;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| CryoablationCryoablation of the mouths of the pulmonary veins and the posterior wall of the left atrium. | Procedure or surgery | Cryoablation |
| Radiofrequency ablationRadiofrequency ablation of pulmonary veins according to the "box isolation" type using a non-fluoroscopic navigation system. | Procedure or surgery | Radiofrequency ablation |
Primary outcome
Cerebral events
Time frame: From the date of ablation until the date of the event, assessed up to 24 months.
The number of patients who had a stroke or acute cerebrovascular accident or a transient ischemic attack within 24 months after ablation.
4 secondary outcomes
Hospital mortality
Time frame: From the date of ablation until the date of death, assessed up to 5 days.
Non-lethal events
Time frame: From the date of ablation to the date of any of the listed events, assessed up to 5 days.
Recurrence of AF
Time frame: From the date of ablation until the date of recurrent atrial fibrillation, assessed up to 24 months.
Long-term mortality
Time frame: From the date of ablation until the date of death, assessed up to 24 months.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Stroke
Not yet recruiting
Temporal Interference Stimulation for Upper-Limb Motor Recovery in Early Subacute Stroke
Acute Ischemic Stroke
RecruitingObservational study
ELATE Study: Evaluating Large-vessel Acute Thrombectomy in Extended Time Window
Acute Ichemic Stroke
Recruiting
Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
Stroke, Upper Extremity Paresis
Recruiting
Early Motor-Cognitive Integrative Training on Cognitive and Motor Performance in Patients With Aneurysmal Subarachnoid Hemorrhage
Subarachnoid Aneurysm Hemorrhage
Not yet recruiting
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
Acute Ischemic Stroke, Basilar Artery Occlusion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Andrey Filatov principal investigator
Bakulev Scientific Center for Cardiovascular Surgery
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Cryoablation and Radiofrequency ablation in people with Stroke and Acute Cerebrovascular Accident, run by Bakulev Scientific Center of Cardiovascular Surgery at 1 site in Russia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 20 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Russia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Andrey Filatov (+7(495) 414-77-02, agfilatov@bakulev.ru), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Cerebral events (time frame: From the date of ablation until the date of the event, assessed up to 24 months.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2026.